Synthetic Biologics, a clinical stage company developing therapeutics to protect the gut microbiome, named Isaac J. Bright, MD, vice president, corporate development.
Here are four points:
1. Dr. Bright will be responsible for strategic business and corporate development activities as well as potential partnering opportunities for the company's drug candidates.
2. Most recently, Dr. Bright led the U.S. private equity investment practice as a partner at Merieux Development.
3. He also previously served as vice president, corporate development and diagnostics for QuantaLife.
4. Synthetic Biologics's drug candidates include SYN-010, designed to reduce methane production in the gut to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004, designed to prevent C. difficile infection, antibiotic associated diarrhea and the emergence of antibiotic resistant organisms.